Siemens Clears Six. The OR Will Never Look the Same.

Siemens Healthineers wins FDA clearance for six Artis systems with Optiq AI, bringing real-time AI image optimization to US interventional labs

13 May 2026

Six AI-powered imaging systems from Siemens Healthineers cleared the FDA on May 12, a milestone that formally plants artificial intelligence inside US operating rooms and interventional labs. All six run on Optiq AI, a deep-learning platform that cuts acquisition noise and adjusts imaging parameters in real time, during live procedures, without a technician manually dialing anything in.

The systems span fluoroscopy, digital subtraction angiography, and standard acquisition imaging. Optiq AI keeps image quality high while holding patient radiation doses to the lowest levels practically achievable. That combination matters most in cardiology suites, minimally invasive surgery theaters, and interventional radiology labs, where image clarity and patient safety pull in opposite directions.

A total of six hardware configurations are cleared. The Artis vision floor, biplane, ceiling, and robotic pheno variants are joined by the Artis icono.explore and Artis genio floor, a lineup designed to cover everything from high-volume academic centers to community hospitals watching every capital line item. Optiq AI is embedded as standard across all six. There is no optional upgrade tier.

Rotating OR teams benefit from shared controls across the entire portfolio, which cuts retraining time and reduces handoff errors. In hospitals running tight schedules under staffing pressure, that consistency keeps rooms moving. "As more complex procedures come to interventional labs, increased precision is of paramount importance," said Kris McVey, head of angiography in advanced therapies at Siemens Healthineers North America, noting that the portfolio was built to serve both clinical need and facility budget realities.

Minimally invasive procedure volumes have been climbing for years. Precise intraoperative imaging has quietly shifted from a selling point to a baseline expectation. For hospitals planning imaging infrastructure investment in 2026, the FDA clearances arrive at an inconvenient moment for competitors. Optiq AI just redrew the floor.